argenx SE ARGX
NasdaqGS
$802.64-9.66 (-1.19%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
argenx has been through a volatile spell after a long run, and the recent swings now put a simple question in front of you as an investor: Is the current share price still in line with what the company's earnings can reasonably support? Over the past 5 years, argenx has delivered a share price gain of 185.3%, which puts a lot of weight on whether its earnings power has kept pace with that move. The company recently halted its Phase 3 Sjögren's trial for futility while reporting encouraging...
European equities traded in the US as American depositary receipts were tracking higher late Friday
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Argenx (ENXTBR:ARGX) is back in focus after twin clinical updates. The company reported positive Phase 2 data for FB102 in celiac disease while deciding to halt its Phase 3 UNITY trial in Sjögren's disease. Over the past month argenx’s share price has come under pressure, with a 30 day share price return of down 18.5% and a 7 day move of down 16.2% around the UNITY trial halt. However, the 5 year total shareholder return of 172.3% shows long term holders have still seen strong gains,...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.
ARGX is in the latest 13F portfolio of 1 of the gurus we follow.
